Bhumsuk Keam: h-index, Total Citations, and Citation Map
Bhumsuk Keam's h-index is 71 (291 i10-index, 22,505+ total citations across 615+ publications) according to Google Scholar as of June 2026. Bhumsuk Keam is affiliated with Department of Internal Medicine, Seoul National University Hospital.
Bhumsuk Keam is a researcher affiliated with Department of Internal Medicine, Seoul National University Hospital, specializing in medical oncology. Their work has been cited 22,505 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Bhumsuk Keam's Citation Metrics
Bibliometric impact based on 615 indexed publications.
- H-Index
- 71
- i10-Index
- 291
- Total Citations
- 22,505
- Citing Countries
- 1
As of June 2026.
Bhumsuk Keam has an h-index of 71 and 22,505 total citations across 615 publications, with research cited by institutions in 1 country.
Download Exports (PNG, CSV, Poster)
Free Viewing Bhumsuk Keam's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
We've mapped 5,000 of 22,505 citations for Bhumsuk Keam
We've shown the most-cited 5,000. Unlock the full crawl (22,455 more citations) to see every institution citing this scholar.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Cabozantinib versus everolimus in advanced renal-cell carcinoma
20151,486
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Bhumsuk Keam's research
Bhumsuk Keam is a researcher in medical oncology at Department of Internal Medicine, Seoul National University Hospital. Their work has been cited 22,505 times across 615 publications (h-index 71), according to Google Scholar.
Their most-cited work, “Cabozantinib versus everolimus in advanced renal-cell carcinoma” (2015), has accumulated 1,486 citations. Other influential works include “Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer” (2018) with 1,066 citations and “Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE …” (2016) with 995 citations.
Citations of Bhumsuk Keam's research come primarily from United States; the citation map above shows the full geographic breakdown.
